The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Il-2Rbeta-Selective Agonists In Combination With An Anti-Ctla-4 Antibody Or An An Anti-Pd-1 Antibody - EP3134123

The patent EP3134123 was granted to Nektar Therapeutics on Feb 17, 2021. The application was originally filed on Feb 20, 2015 under application number EP15721044A. The patent is currently recorded with a legal status of "Revoked".

EP3134123

NEKTAR THERAPEUTICS
Application Number
EP15721044A
Filing Date
Feb 20, 2015
Status
Revoked
Mar 8, 2024
Publication Date
Feb 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GREINERNov 17, 2021GREINER -

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2006138572
DESCRIPTIONWO2012065085
DESCRIPTIONWO2012065086
INTERNATIONAL-SEARCH-REPORTWO2006121168
INTERNATIONAL-SEARCH-REPORTWO2012065086
OPPOSITIONIN2014DEL3087
OPPOSITIONIN2014DEL499
OPPOSITIONWO2006121168
OPPOSITIONWO2012065086
OPPOSITIONWO2015125159

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents